Fixed Dose Combination drugs for Secondary Cardiovascular Prevention

back home
Print version Increase text Decrease text
Contract/Grant agreement number
: 241559
EC contribution
: € 2,999,999.00
: 36 months
Starting date
: 01/07/2010
: Cardiovascular diseases, myocardial infarction, secondary prevention, treatment, treatment adherence, fixed dose combination, developing countries, clinical trial, chronic diseases
Project web-site

FOCUS aims to test the Fixed-Dose-Combination (FDC) concept for secondary cardiovascular disease (CVD) prevention, and for a better understanding of socio-economic factors that influence access and adherence to CVD treatment. The FOCUS FDC pill is a single-day pill containing three active components of well-demonstrated efficacy. It can be produced and administrated at a much lower cost than conventional equivalents and is thus suitable for widespread use in resource-poor countries. The FDC pill will be tested in two complementary controlled clinical studies: a descriptive non-interventional study followed by an interventional randomised trial. The studies will analyse data collected at 40 clinical sites in Europe and 40 sites in three middle-income developing countries. FOCUS is an international collaboration between research institutes, clinicians, pharma Industry, small and medium-sized enterprises (SMEs) and scientific organisations.

[+] Read More